Intermediate AMD - Epidemiology Forecast - 2034

Key Highlights

• Aplastic anemia is a rare and severe nonmalignant disease characterized by autoimmune destruction of early hematopoietic cells. Its global incidence rate ranges from 0.7 to 7.4 cases per million inhabitants per year, with higher rates in Asia compared to Europe and the United States.
• According to the Aplastic Anemia and MDS International Foundation, about 600-900 patients of aplastic anemia are diagnosed each year in the US.
• According to the Aplastic Anemia Trust and Leukemia Care, it is estimated that between 100 and 150 people will be diagnosed across the UK every year, i.e., around 2 people for every 1,000,000 of the population.
• Based on severity, severe and very severe aplastic anemia patients contributes roughly 65%-80% of the total aplastic anemia patient population.

This report delivers an in-depth understanding of aplastic anemia, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Aplastic Anemia Disease Understanding

Aplastic Anemia Overview

Aplastic anemia refers to the syndrome of chronic primary hematopoietic failure from injury leading to diminished or absent hematopoietic precursors in the bone marrow and attendant pancytopenia. The symptoms of aplastic anemia occur because the bone marrow fails to produce enough blood cells. Some individuals may have mild symptoms that remain stable for many years; others may have serious symptoms that can progress to life-threatening complications. Individuals with anemia may experience tiredness, increased need for sleep, weakness, lightheadedness, dizziness, irritability, headaches, pale skin color, difficulty breathing, and cardiac symptoms like chest pain.

Aplastic Anemia Diagnosis

The rarity of aplastic anemia, coupled with its overlap with other bone marrow failure syndromes, poses a diagnostic challenge. Except for findings related to bleeding or infections, the examination presents mainly negative characteristics: absence of lymphadenopathy, no enlarged spleen or liver, and no infiltration of any other organ. Bone marrow (BM) aspiration and biopsy are essential procedures for diagnosing aplastic anemia. Cytogenetic abnormalities can be detected in up to 12-15% of otherwise typical aplastic anemia patients, making systematic cytogenetic investigations essential for all aplastic anemia patients. Molecular analysis, including next-generation sequencing (NGS), has become increasingly instrumental in comprehending the pathophysiology of diseases.

Aplastic Anemia Epidemiology

The aplastic anemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of aplastic anemia, severity-specific cases of aplastic anemia, and age-specific cases of aplastic anemia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The total incident cases of aplastic anemia in the 7MM comprised ~2,500 cases in 2023 and are projected to increase during the forecast period.
• Among the 7MM, Japan accounted for the highest number of incident cases of aplastic anemia, i.e., ~800 cases in 2023.
• According to estimates, aplastic anemia is more common in the older population; the highest incident cases were in the age group of =60 years, accounting for ~60% of cases, and ~40% were < 60 in 2020 in the 7MM.
• In 2023, among EU4 and the UK, Germany accounted for the largest number of aplastic anemia cases, whereas Spain occupied the bottom of the ladder.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on the aplastic anemia evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors; MD, FACS, Head of the Universities, and others.

The analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the East Tennessee State University, Düsseldorf Clinics Association, Duke University School of Medicine, etc., were contacted. Their opinion helps understand and validate aplastic anemia epidemiology trends.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of aplastic anemia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts of disease progression has been provided.
• The report provides an edge while developing business strategies, understanding trends, and expert insights in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Aplastic Anemia Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

Aplastic Anemia Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Aplastic Anemia Epidemiology Segmentation

Aplastic Anemia Report Assessment

• Current Diagnostic Practices
• Unmet Needs

FAQs

• What are the disease risks, burdens, and unmet needs of aplastic anemia? What will be the growth opportunities across the 7MM concerning the patient population with aplastic anemia?
• What is the historical and forecasted aplastic anemia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What is the severity-specific distribution of aplastic anemia in the 7MM?
• What is the age-specific rate of aplastic anemia?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the diagnosed cases of aplastic anemia in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.